[Asia Economy Reporter Cho Hyun-ui] Chong Kun Dang announced on the 27th that the 20mg product of the dyslipidemia treatment drug 'Lipirou' showed excellent efficacy and cost-effectiveness.
Chong Kun Dang recently presented these clinical trial results at the American Heart Association (AHA) Annual Scientific Sessions held online. This study was conducted to verify the efficacy and cost-effectiveness of Lipirou 10mg and 20mg in Korean patients with high-risk hypercholesterolemia.
The research team led by Professor Kim Jin-won of the Department of Cardiology at Korea University College of Medicine divided 237 patients classified as high-risk and very high-risk according to the Korean dyslipidemia guidelines into two groups, administering Lipirou 10mg and 20mg respectively for 12 weeks. Afterwards, they evaluated the levels of low-density lipoprotein cholesterol (LDL-C), which is harmful to the body, and conducted a cost-effectiveness assessment.
The study results showed that the LDL-C levels in the 10mg group decreased by 33.5% after 12 weeks. In the 20mg group, LDL-C levels decreased by 42.4%, indicating that cholesterol levels were lowered in both groups.
In the secondary endpoint of cost-effectiveness evaluation, the average cost-effectiveness ratio (ACER) for the 10mg dose was 2,604 KRW per 1% reduction in cholesterol levels. For the 20mg dose, it was 2,074 KRW, confirming it was more than 20% cheaper.
A Chong Kun Dang official stated, "This study is significant in that it simultaneously evaluated the efficacy and cost-effectiveness by dosage in domestic high-risk patients," adding, "The results of this study provide another standard for drug prescription in the treatment of dyslipidemia patients."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
